# Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

> **NCT06425003** · PHASE1 · COMPLETED · sponsor: **Calico Life Sciences LLC** · enrollment: 7 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** [14C] ABBV-CLS-7262

## Key facts

- **NCT ID:** NCT06425003
- **Lead sponsor:** Calico Life Sciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-21
- **Primary completion:** 2024-07-12
- **Final completion:** 2024-07-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06425003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06425003, "Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06425003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*